

23 April 2009

Northwest Biotherapeutics, Inc.
(the "Company")

New Issue of Shares and Total Voting Rights

Bethesda, MD Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO) announces today that further to the Company's announcement of 7 April 2009, 1,577,019 new ordinary shares of 0.001 each (Reg S) are expected to be admitted to trading on AIM on 24 April 2009. The Company's issued share capital will therefore comprise 40,360,878 Reg S common stock of 0.001 each in the Company (AIM: NWBS) and 4,709,094 unrestricted common stock of 0.001 each in the Company (AIM: NWBT).

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

For further information, please contact:

Northwest Biotherapeutics, Inc.

Alton L. Boynton, Chief Executive Officer

+1 240 497 9024

Buchanan Communications

Lisa Baderon (lisab@buchanan.uk.com) / Mary-Jane Johnson / +44 (0)20 7466 5000

Catherine Breen

Collins Stewart Europe Limited

Adrian Hadden/ Adam Cowen

+44 (0)20 7523 8350

This information is provided by RNS
The company news service from the London Stock Exchange